Jason Shafrin, Ph.D., Senior Managing Director, shares his insights on “Biosimilar’s Role in Improving Patient Access” in a recent podcast episode of Prescription for Better Access, where he argues that improving access to biosimilars after reference product loss of exclusivity is a better approach for lowering drug prices compared to top-down government mandates like IRA, PDAB and 340B.
Access audio-only podcast here.
Key Contacts